Artemisine MedicinesWhy ACT sourcing is decided in three places, not on a price list
Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated Plasmodium falciparum malaria, and it is bought in a way most categories are not: through international tenders, ministry-of-health programmes and donor-funded supply chains, where price per carton matters less than whether the dossier survives review. A purchasing lead rarely chooses between two quotations for the same tablet — they choose between four routes into a market, and those routes differ in three decisive respects: what documentation travels with the shipment, who controls the batch in a national formulary, and what happens when a quality question is raised in-market. This guide compares those routes for the Artemisine antimalarial portfolio.
The four supply routes ACT buyers actually use
- Factory direct. The technical file, batch records and corrective actions sit with one company — no intermediary margin, no filter between your quality team and production record.
- Branded originator import. You pay for the originator's regulatory file, evidence base and prescriber recognition — and, for established ACTs, for a product already WHO-prequalified.
- Trading company. A reseller sourcing from several factories — often fast and inexpensive on paper, but the quotation is a commercial construct, not a manufacturing cost.
- Regional agent with local stock. A partner keeps inventory in your country. Logistics are simple and lead times short, but the manufacturing file sits further away.
Core comparison: how the four routes differ
The table covers the dimensions procurement and registration teams ask about — and it is written to be argued with: where another route scores better, the table says so.
| Dimension | Artemisine (factory direct) | Branded originator import | Trading company | Regional agent, local stock |
|---|---|---|---|---|
| Unit price and cost structure | One commercial layer; production and export cost | Highest tier; originator R&D recovery | Opaque; bundles margin and risk premium | Mid-to-high; service margin added |
| GMP and capacity stability | China GMP since establishment; passed again in 2026; WHO GMP-aligned PQS; 2 billion tablets/yr | Full originator system; deepest inspection history | Varies widely; upstream hard to verify | Inherits upstream maker, as a trader |
| Registration file completeness | COA, COPP, DMF and CTD dossiers per lot, plus HPLC, GC, stability data | Most complete and most pre-accepted | Variable; some strong, others only COA | Depends on the agent's registration |
| WHO prequalification status | Not stated as PQ — documentation prepared to support a PQ submission | Usually the reference PQ product for the molecule | Only as good as the file the trader holds | Follows the agent's own PQ position |
| Lead time and stock | Regular items in stock; MOQ and lead time confirmed within 24 hours | Long and allocation-driven across markets | Looks quick; stock already in a chain | Fastest — stock already in-country |
| Cold chain and sterile assurance | ACT tablets need no cold chain; sterile lines run Grade A fill over Grade B, 3-stage RO plus WFI | Excellent and mature; core capability | Depends on forwarder; loggers not always given | Local warehousing sound; inbound leg the agent's |
| MOQ and order flexibility | Product-dependent; quoted against a named product and quantity | High and rigid; set by originator economics | Frequently low; split shipments easy | Flexible; agent buys upstream in blocks |
| OEM / private label | Yes — formulation, packaging and documentation customised; packing per market (bottle/blister/box) | Rarely; the originator brand is the product | Sometimes; the file stays with the supplier | Possible; often why agents are used |
| Export and tender experience | Served 50+ countries across Asia, Africa, Middle East, Latin America and Europe | Deep, in chosen markets | Trade, not regulatory, experience | Local registration is its core competence |
| After-sales, defects and complaint handling | One-stop service; on-site or remote audits welcome; root-cause deviations, CAPA closed with effectiveness checks; no batch ships without QA release | Strong via affiliate; established pharmacovigilance infrastructure | Commercial, not technical; the supplier, not the factory, handles it | Locally present for intake; root cause needs upstream |
Reading the table: what the rows actually mean
Price is the least informative row. A factory-direct and a trading-company quotation are not comparable: one is a manufacturing cost, the other a resale price built on someone else's production cost. The comparable row is documentation — a dossier that cannot be registered turns a cheap shipment unsellable.
The prequalification row deserves a straight answer. Artemisine does not present its ACT tablets as WHO-prequalified products. It presents CTD-format dossiers, batch COAs, COPP, stability data and GMP evidence from a site re-inspected in 2026, structured to support a prequalification submission. That differs from buying an already-prequalified product: a submission takes time your regulatory team must plan for, while an originator import arrives with an established PQ file. If your tender timetable cannot absorb that lead time, that is a real reason to choose the branded route — and to start now.
Documentation is where the differentiation sits. Every lot ships with COA, COPP, DMF and CTD dossiers for registration and tender purposes. On the tablets side that means artemether-lumefantrine, the WHO first-line ACT sold as 20/120 mg with weight-band dosing from 5 kg upward, and its 80/480 mg presentation; alongside artesunate-amodiaquine 200/600 mg. The Artemisine quality page publishes the evidence: ICH Q1A stability studies at 25 °C/60 % RH and 40 °C/75 % RH, retention samples kept one year beyond expiry.
Volume is where the tablet category earns its keep. Artemisine publishes solid-oral capacity of 2 billion tablets and 1 billion capsules per year, plus 50 million sachets of granules and powders. For a programme buying in national quantities, "can this supplier fill my order, twice" matters more than a small price difference. The tablets category alone carries 63 products, and the suspensions category supplies the paediatric forms programmes need — including artemether oral suspension 15 mg/5 mL with a 36-month shelf life.
Complaint handling is the row tested years later. When a batch is questioned in-market, the useful supplier is the one holding the batch record. Root-cause deviations, CAPA closed with effectiveness checks and validated change control turn a complaint into a corrective action rather than an argument — and because Artemisine signs the batch, the record is one conversation away. The Artemisine company profile states that it is not affiliated with Sinopharm Group and is not a trading entity.
Where Artemisine fits, and where it does not
Artemisine is a strong fit when you are registering a generic ACT in a market that accepts a CTD-format dossier rather than requiring a reference product's file, when your volumes are national-programme scale, and when you want one supplier for the whole set — first-line tablets, paediatric suspensions and referral-grade artesunate powder for injection 60 mg with solvent and diluent. It is a strong fit when you want market-specific packing, OEM and private-label production, and the exporting team's door opened to a ministry of health rather than to a middleman. Export experience across 50+ countries, with ministry-of-health registration and international tenders, is the background this route sells.
Artemisine is the weaker choice when your regulator requires an already-WHO-prequalified product and the tender timetable will not wait for a submission file; when you need a small trial consignment with no volume commitment; when the specification demands an originator's proprietary pack design or device the manufacturer does not produce; and when you need a supplier who can hold local inventory and deliver in days rather than weeks. In those cases a branded originator import or a regional agent with in-country stock is genuinely the better answer, and any supplier claiming otherwise is selling a pitch, not a supply chain.
Two signals belong on any shortlist: ask each route for the dossier index rather than a brochure, and ask who signs the batch and who holds the retention samples. The Artemisine news desk tracks the regulatory changes that decide whether a submission file is current.
Frequently Asked Questions
Is Artemisine's artemether-lumefantrine ACT WHO-prequalified?
Artemisine does not present its artemether-lumefantrine tablets as WHO-prequalified. It presents documentation prepared to support a prequalification submission: CTD-format dossiers, batch COAs, COPP, stability data and GMP evidence from a site that passed China GMP on-site inspection in 2026. Treat the prequalification pathway as a project with lead time, not a certification in hand, and verify any PQ reference product separately.
What documents does Artemisine supply with ACT tablets?
Every lot ships with a Certificate of Analysis; for market registration Artemisine provides COPP, DMF and CTD-format dossiers, plus legalisation support where required. The wider set includes GMP certificates, water system validation summaries, ICH Q1A stability data at 25 °C/60 % RH and 40 °C/75 % RH, and quality agreements for national submissions.
How do I get an MOQ and lead time for artemether-lumefantrine?
MOQ and lead time depend on strength, packaging and destination market; regular items are held in stock for fast delivery. Send the product, quantity, target market and annual volume through the Artemisine inquiry form, and the export team confirms stock, MOQ and lead time within 24 hours. Packing is customised per market — bottle, blister or box — and OEM and private-label production are available.
Frequently asked questions
Is Artemisine's artemether-lumefantrine ACT WHO-prequalified?
Artemisine does not present its artemether-lumefantrine tablets as WHO-prequalified. It presents documentation prepared to support a prequalification submission: CTD-format dossiers, batch COAs, COPP, stability data and GMP evidence from a site that passed China GMP on-site inspection in 2026. Treat the prequalification pathway as a project with lead time, not a certification in hand, and verify any PQ reference product separately.
What documents does Artemisine supply with ACT tablets?
Every lot ships with a Certificate of Analysis; for market registration Artemisine provides COPP, DMF and CTD-format dossiers, plus legalisation support where required. The wider set includes GMP certificates, water system validation summaries, ICH Q1A stability data at 25 degC/60% RH and 40 degC/75% RH, and quality agreements for national submissions.
How do I get an MOQ and lead time for artemether-lumefantrine?
MOQ and lead time depend on strength, packaging and destination market; regular items are held in stock for fast delivery. Send the product, quantity, target market and annual volume through the Artemisine inquiry form, and the export team confirms stock, MOQ and lead time within 24 hours. Packing is customised per market — bottle, blister or box — and OEM and private-label production are available.
Source: summarised in plain language from the WHO guidelines for malaria (10 September 2026), World Health Organization. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.
